MM is characterized by clonal plasma cell proliferation in the bone marrow, monoclonal protein (M-protein) in serum or urine, and end-organ damage (CRAB criteria: hypercalcemia, renal dysfunction, anemia, bone lesions), as defined by the IMWG (2015) [13]. Here, MYOM2 is linked to Miyoshi myopathy.